Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Net loss per share (Details)

Net loss per share (Details) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Antidilutive securities excluded from the computation of diluted net loss per share
Antidilutive securities excluded from computation of earnings per share (in shares)	20,356	18,549
Employee Stock Option
Antidilutive securities excluded from the computation of diluted net loss per share
Antidilutive securities excluded from computation of earnings per share (in shares)	20,077	18,281
Warrant to purchase common stock
Antidilutive securities excluded from the computation of diluted net loss per share
Antidilutive securities excluded from computation of earnings per share (in shares)	200	200
Employee Stock
Antidilutive securities excluded from the computation of diluted net loss per share
Antidilutive securities excluded from computation of earnings per share (in shares)	79	68

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References + Details